Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Organovo Holdings, Inc. (NASDAQ: ONVO).

Full DD Report for ONVO

You must become a subscriber to view this report.


Recent News from (NASDAQ: ONVO)

Key events next week - healthcare
Noteworthy events during the week of November 4 - 10 for healthcare investors. More news on: Dare Bioscience, Inc., EyePoint Pharmaceuticals, Inc., Aduro Biotech, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: November, 02 2018 10:12
Organovo Announces Release Date for Fiscal Second-Quarter 2019 Financial Results
SAN DIEGO, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) will host a conference call on Thursday, November 8, 2018 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fiscal second-quarter 2019 operating and financial highlights. In a...
Source: GlobeNewswire
Date: October, 18 2018 08:05
Report: Exploring Fundamental Drivers Behind Shenandoah Telecommunications, Nova Measuring Instruments, FRP, National Fuel Gas, Organovo, and Sierra Wireless - New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Oct. 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Shenandoah Telecommunications Co (NASDAQ:SHEN), Nova Measuring Instrument...
Source: GlobeNewswire
Date: October, 17 2018 07:30
Organovo to Present New Preclinical Data on 3D Bioprinted Human Liver Tissues for the Treatment of Tyrosinemia I at the Liver Meeting® 2018 (AASLD)
SAN DIEGO, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious adult and pediatric liver diseases, today announced it will present...
Source: GlobeNewswire
Date: October, 15 2018 08:05
Organovo to Present at 2018 Cell & Gene Meeting on the Mesa
SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious adult and pediatric liver diseases, today announced that Chief Exe...
Source: GlobeNewswire
Date: September, 26 2018 08:05
Recent Analysis Shows Ellie Mae, Organovo, Calithera Biosciences, Whirlpool, Marathon Oil, and Infinera Market Influences - Renewed Outlook, Key Drivers of Growth
NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ellie Mae, Inc. (NYSE:ELLI), Organovo Holdings, Inc. (NASDAQ:ONVO), Calit...
Source: GlobeNewswire
Date: August, 14 2018 20:15
Premarket Losers as of 9:05 am (8/10/2018)
GEMP   -65%  on terminating Phase 2a clinical trial assessing gemcabene in pediatric patients with NAFLD. More news on: Gemphire Therapeutics, Corcept Therapeutics Incorporated, Avalara, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 10 2018 09:15
Organovo Holdings Q1 revenues down 30%
Organovo Holdings ( ONVO ) Q1 results : Revenues: $0.7M (-30.0%); Products and services: $0.5M (-44.4%); Collaborations and licenses: $0.04M (-6.5%); Grants: $0.1M. More news on: Organovo Holdings, Inc., Healthcare stocks news, Earnings news and commentary, , Read more ...
Source: SeekingAlpha
Date: August, 10 2018 06:51
Organovo Holdings, Inc. (ONVO) CEO Taylor Crouch on Q1 2019 Results - Earnings Call Transcript
Organovo Holdings, Inc. (ONVO) Q1 2019 Results Earnings Conference Call August 9, 2018, 05:00 PM ET Executives Steve Kunszabo - IR Taylor Crouch - CEO Craig Kussman - CFO Analysts Matthew Cross - Jones Trading Ed Arce - H.C. Wainwright & Company Presentation Op...
Source: SeekingAlpha
Date: August, 09 2018 19:48
Organovo Reports Fiscal First-Quarter 2019 Results; Company Outlines and Expands Key Clinical Development Goals
Pre-Investigational New Drug (“IND”) meeting with the FDA expected to be held in calendar 2019 Lead IND program for Alpha-1-antitrypsin deficiency (“A1AT”) expected to commence IND-enabling studies in second half of calendar 2019 and to submit an IND in...
Source: GlobeNewswire
Date: August, 09 2018 16:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-101.021.0151.040.9901216,479
2018-12-071.001.031.031.00235,646
2018-12-060.991.0151.030.97312,055
2018-12-051.001.011.041.00596,891
2018-12-041.001.0151.041.00529,341

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1040,81895,04842.9446Short
2018-12-0726,214184,86414.1802Cover
2018-12-0646,713189,87224.6024Cover
2018-12-0427,191231,94111.7232Cover
2018-12-0331,756179,61517.6800Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ONVO.


About Organovo Holdings, Inc. (NASDAQ: ONVO)

Logo for Organovo Holdings, Inc. (NASDAQ: ONVO)

Organovo designs and creates functional human tissues using a proprietary three dimensional bioprinting technology. The Company focuses on developing a range of human tissues and disease models for medical research and therapeutic applications. The Company s NovoGen three dimensional bioprinting technology employs a specialized automated platform that works across all tissue and cell types. Organovo s bioprinter was named one of the Best Inventions of by TIME Magazine and Organovo has been recognized as one of the most innovative companies of by MIT s Technology Review. Organovo is helping pharmaceutical partners develop never before available human biological disease models in three dimensions that hold the potential to transform the business of therapeutic drug discovery and development. Organovo is also developing direct tissue therapies where precise structure and architecture may deliver the best clinical outcomes. Organovo leads the way in solving complex medical research problems and building the future of medicine.

 

Contact Information

 

 

Current Management

  • Keith Murphy / CEO, President
  • Barry D. Michaels / CFO, Corporate Secretary
  • Michael Thomas Renard / EVP
  • Eric Michael David / CSO
  • Sharon Collins Presnell / CTO
  • Keith Murphy / Chairman
  • Andras Forgacs /
  • James T. Glover /
  • Tamar D. Howson /
  • Robert Baltera, Jr. /
  • Adam K. Stern /

Current Share Structure

  • Market Cap: $162,928,880 - 05/11/2018
  • Authorized: 150,000,000 - 02/03/2012
  • Issue and Outstanding: 110,835,973 - 02/01/2018
  • Float: 50,000,000 - 03/31/2013

 


Recent Filings from (NASDAQ: ONVO)

Filing Type: CT ORDERFiling Source: edgar
Filing Date: May, 17 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: March, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 16 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: March, 16 2018
Post-effective amendment to an S-Type filing
Filing Type: POS AMFiling Source: edgar
Filing Date: March, 16 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: February, 08 2018
Simplified registration form
Filing Type: S-3Filing Source: edgar
Filing Date: February, 08 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: January, 29 2018

 

 


Daily Technical Chart for (NASDAQ: ONVO)

Daily Technical Chart for (NASDAQ: ONVO)


Stay tuned for daily updates and more on (NASDAQ: ONVO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ONVO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ONVO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ONVO and does not buy, sell, or trade any shares of ONVO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/